Sean E. Aeder

Array ( [id] => 17369987 [patent_doc_number] => 20220025039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => METHODS FOR TREATING DYSREGULATED LIPID METABOLISM [patent_app_type] => utility [patent_app_number] => 17/296506 [patent_app_country] => US [patent_app_date] => 2019-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369987 [patent_doc_number] => 20220025039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => METHODS FOR TREATING DYSREGULATED LIPID METABOLISM [patent_app_type] => utility [patent_app_number] => 17/296506 [patent_app_country] => US [patent_app_date] => 2019-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17473979 [patent_doc_number] => 20220081483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => METHODS AND COMPOSITIONS FOR REDUCING NUMBERS OR ELIMINATING HIV-INFECTED CELLS [patent_app_type] => utility [patent_app_number] => 17/295084 [patent_app_country] => US [patent_app_date] => 2019-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11581 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17295084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343687 [patent_doc_number] => 20220010018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/294560 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299940 [patent_doc_number] => 20210395779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => TWO-GENE VECTORS FOR GENERATING CAR-T CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/291580 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18165255 [patent_doc_number] => 20230031853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => COMPOSITIONS AND METHODS FOR THE CYTOPLASMIC DELIVERY OF ANTIBODIES AND OTHER PROTEINS [patent_app_type] => utility [patent_app_number] => 17/294401 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17874376 [patent_doc_number] => 11446369 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => Compositions and methods comprising KLK3 or FOLH1 antigen [patent_app_type] => utility [patent_app_number] => 16/672362 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 26 [patent_no_of_words] => 38944 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16672362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336095 [patent_doc_number] => 20220002426 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => NOVEL AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES [patent_app_type] => utility [patent_app_number] => 17/290340 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15768833 [patent_doc_number] => 20200115434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/667781 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16667781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20262980 [patent_doc_number] => 12433948 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Aqueous pharmaceutical formulations [patent_app_type] => utility [patent_app_number] => 17/290092 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 2 [patent_no_of_words] => 2435 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800231 [patent_doc_number] => 20200123258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => TARGETING B CELLS TO ENHANCE RESPONSE TO IMMUNE CHECKPOINT BLOCKADE [patent_app_type] => utility [patent_app_number] => 16/661867 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16661867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090529 [patent_doc_number] => 20200199251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38 [patent_app_type] => utility [patent_app_number] => 16/660415 [patent_app_country] => US [patent_app_date] => 2019-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16660415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19948390 [patent_doc_number] => 12319737 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => NK engager molecules and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/285447 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 53 [patent_no_of_words] => 9583 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15524841 [patent_doc_number] => 20200054726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => CANCER THERAPY USING A VACCINE IN COMBINATION WITH A CELL-BASED IMMUNOTHERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 16/597582 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16597582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432445 [patent_doc_number] => 20200030405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/595430 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16595430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408073 [patent_doc_number] => 20200024358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => TRISPECIFIC ANTIGEN BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 16/593704 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960080 [patent_doc_number] => 20220340660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => BIOMARKERS FOR ANTI-TIGIT ANTIBODY TREATMENT [patent_app_type] => utility [patent_app_number] => 17/762530 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25876 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681323 [patent_doc_number] => 20200095325 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => AGENTS THAT MODULATE IMMUNE CELL ACTIVATION AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/572142 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47529 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16572142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16833260 [patent_doc_number] => 11009507 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Methods and diagnostics for cancer detection and treatment monitoring [patent_app_type] => utility [patent_app_number] => 16/570747 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 16669 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16192139 [patent_doc_number] => 20200232988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => SIGNATURES AND DETERMINANTS ASSOCIATED WITH PROSTATE CANCER PROGRESSION AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/552587 [patent_app_country] => US [patent_app_date] => 2019-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16552587 [rel_patent_id] =>[rel_patent_doc_number] =>)